依达拉奉右莰醇早期治疗急性脑梗死的疗效及对脑血管储备功能、肢体功能、神经损伤因子的影响

Efficacy of Edaravone and Dexborneol in the Early Treatment of Acute Cerebral Infarction and Its Effect on Cerebrovascular Reserve Capacity,Limb Function and Nerve Injury Factors

目的:探讨依达拉奉右莰醇早期治疗急性脑梗死(ACI)的疗效及对脑血管储备功能、肢体功能、神经损伤因子的影响。方法:选取2020年4月~2021年10月某院收治的100例ACI患者作为研究对象,依据随机数字表法分为观察组和对照组,每组50例。观察组于输注注射用阿替普酶后即给予依达拉奉右莰醇注射用浓溶液治疗,对照组于输注注射用阿替普酶24h后给予依达拉奉右莰醇注射用浓溶液治疗。比较两组患者脑血管储备功能[脑血管储备(CVR)、大脑中动脉搏动指数(PI)及血流速度(BFR)]、肢体功能(感觉功能、平衡能力、主动完成活动能力、运动变换能力、关节活动度)、神经损伤因子[过氧化还原酶1(PRDX1)、网膜素-1(omentin-1)、甲壳质酶蛋白-40(YKL-40)],临床疗效及不良反应发生情况。结果:治疗后,观察组PI低于对照组,CVR和BFR高于对照组(P<0.05);观察组感觉功能、平衡能力、主动完成活动能力、运动变换能力、关节活动度得分高于对照组(P<0.05);观察组PRDX1、YKL-40水平低于对照组,omentin-1水平高于对照组(P<0.05)。观察组总有效率高于对照组(P<0.05);两组不良反应总发生率比较无统计学差异(P>0.05)。结论:依达拉奉右莰醇早期治疗ACI可有效保护脑血管储备功能,增强肢体功能,改善血清神经损伤因子水平,提高疗效,且不增加不良反应的发生风险。

Objective:To investigate the effect of edaravone and dexborneol in early treatment of acute cerebral infarction(ACI)and its effect on cerebrovascular reserve capacity,limb function and nerve injury factors.Methods:A total of 100 ACI patients treated in a hospital from April 2020 to October 2021 were selected and divided into observation group and control group by random number table,with 50 patients in each group.The observation group was given edaravone and dexborneol concentrated solution for injection immediately after infusion of alteplase for injection,and the control group was given edaravone and dexborneol concentrated solution for injection 24 hours after the infusion of alteplase for injection.The cerebrovascular reserve capacity[cerebrovascular reserve(CVR),middle cerebral artery pulsatility index(PI)and blood flow rate(BFR)],limb function(sensory function,balance ability,ability to perform activities actively,motor change ability,joint range of motion),nerve injury factors[peroxiredoxin 1(PRDX1),omentin-1,chitinase-like protein-40(YKL-40)],clinical effect and adverse reactions were compared between the two groups.Results:After treatment,PI in the observation group were lower and CVR and BFR were higher than those in the control group(P<0.05).Scores of sensory function,balance ability,ability to perform activities actively,motor change ability and joint range of motion in observation group were higher than those in control group(P<0.05);the levels of PRDX1 and YKL-40 were lower and the level of omentin-1 was higher in the observation group than those in the control group(P<0.05).The total effective rate in observation group was higher than that in the control group(P<0.05).The No statistically significant difference in the total incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Edaravone and dxborneol for early treatment of ACI can effectively protect the cerebrovascular reserve capacity,enhance limb function,improve levels of serum nerve injury factors,and prompt the efficacy,and does not increase risks of adverse reactions.